Your browser doesn't support javascript.
loading
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.
Jimenez, Camilo; Subbiah, Vivek; Stephen, Bettzy; Ma, Junsheng; Milton, Denai; Xu, Mingxuan; Zarifa, Abdualrazzak; Akhmedzhanov, Fechukwu Omolara; Tsimberidou, Apostolia; Habra, Mouhammed Amir; Rodon Anhert, Jordi; Fu, Siqing; Naing, Aung.
Afiliação
  • Jimenez C; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Stephen B; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Ma J; Department of Biostatistics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Milton D; Department of Biostatistics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Xu M; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Zarifa A; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Akhmedzhanov FO; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Tsimberidou A; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Habra MA; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Rodon Anhert J; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Fu S; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Naing A; Department of Investigational Cancer Therapeutics; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancers (Basel) ; 12(8)2020 Aug 16.
Article em En | MEDLINE | ID: mdl-32824391
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça